DCM
KPTI icon

Delpha Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Delpha Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-29
Closed -$4K – 695
2017
Q4 		$4K Buy
+29
New +$4.66K ﹤0.01% 1353

Other funds holding KPTI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Delpha Capital Management's KPTI Position: Q1 2018 in Review

Delpha Capital Management sold out of Karyopharm Therapeutics (KPTI) in Q1 2018, closing a stake of 29 shares — an estimated $4K sold.

Delpha Capital Management first reported a position in KPTI in Q4 2017 and held it in 1 quarter. The position peaked at $4K in Q4 2017. 88 funds tracked by Wall St. Rank hold KPTI as of Q1 2018.

  • Delpha Capital Management reported no remaining Karyopharm Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 29 Karyopharm Therapeutics shares in Q1 2018, an estimated $4K.
  • Delpha Capital Management first reported a position in Karyopharm Therapeutics in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Karyopharm Therapeutics position peaked at $4K in Q4 2017.
  • 88 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.